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ABSTRACT 
Objective: In the present investigation, an attempt was made to improve the surface characters and solubility of the drug by solid dispersion and 
coating it on the nonpareil sugar beads as pellets. 
Methods: Telmisartan solid dispersions were prepared by kneading method using soluplus. Crospovidone was added as disintegrant in pellets. 
Telmisartan pellets were prepared by dissolving soluplus and crospovidone in ethanol in different ratios and coated on nonpareil sugar beads as a 
drug layer by pan coating technique. Various physicochemical parameters like particle size, friability, angle of repose and drug content were 
evaluated for the prepared solid dispersions and pellet formulations. In vitro dissolution studies were carried out in pH 7.5 phosphate buffer using 
USP apparatus II. Fourier Transform Infrared Spectrometry, Differential Scanning Calorimetry and Scanning Electron Microscopic analysis were 
performed for solid dispersions, pellet formulations and its polymers to determine the interactions and surface characteristics. 
Results: The physicochemical parameters were within the specified I. P limits. It was observed that the solid dispersion formulation TS5 
containing 1:5 ratio of telmisartan to soluplus showed better dissolution rate to the extent of 1.143 folds and 2.033 folds when compared to a 
marketed formulation and the pure drug, respectively. Similarly, pellet formulation TP3 containing 1:3 ratio of telmisartan to soluplus showed an 
improved dissolution rate to the extent of 1.221 folds and 2.170 folds when compared to the marketed formulation and the pure drug, respectively. 
FTIR and DSC analysis revealed that there was no major interaction between the drug and the excipients.  
Conclusion: From the present study, it was observed that the solubility of telmisartan was enhanced by soluplus in pellet formulations when 
compared to solid dispersions. 
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INTRODUCTION 
Multiparticulate oral drug delivery systems have acquired a centre stage 
in the arena of pharmaceutical research and development, thus provide 
greater opportunities in extending the first step of future pharmaceutical 
development. Multiparticulate drug delivery systems include pellets, 
granules, micro particles (like microspheres, microcapsules, and 
nanoparticles), mini tablets, mini depots, multiparticulate pulsatile drug 
delivery systems. Pelletized dosage forms date back to the 1950s, when 
the first product was introduced to the market. In 1949, research 
scientists of SmithKline and French developed tiny drug pellets that are 
filled into capsules. Since then, these dosage forms have gained 
considerable popularity because of their distinct advantages such as 
enhancement of drug dissolution; ease of coating with desirable release 
characteristics like sustained, controlled, delayed, site-specific or 
pulsatile delivery of drug from coated pellets; uniform packing; ease of 
capsule filling because of better flow properties due to its spherical 
shape; even distribution in the GI tract and less GI irritation. Pellets are 
obtained from diverse starting materials of fine powders or granules of 
bulk drugs and excipients utilizing different pelletization techniques 
[1]. Pellets intended for oral use are administered in the form of hard 
gelatin capsules or disintegrating tablets which quickly liberate their 
contents in the stomach and gets distributed throughout the 
gastrointestinal tract without loss of the depot effect and acts as self-
contained depots [2, 3]. Pellets are prepared by 
different pelletization techniques like agitation by balling, compaction by 
compression and extrusion spheronization, layering and globulation by 
spray drying and spray congealing. 
In the present experiment nonpareil sugar beads were coated with 
drug solution by layering technique. A well-
controlled pelletization technique in which drug is layered onto 
starter seed materials which are coarse material or nonpareil, in 
powder, solution or suspension form with the aid of binder that 
assists heterogeneous pellets, consists of an inner core region and an 
outer shell region of a different composition [4, 5]. The nonpareil 
seeds must have spherical shape, smooth surface, uniform particle 
size distribution for uniform coating [6]. The concentration of the 
binder is based on the choice of the drug because it influences 
physical as well as mechanical properties of pellets and drug release 
from coated pellets. Commonly used binders include gelatin, 
povidone, carboxymethyl cellulose, hydroxyl propyl methyl 
cellulose, hydroxypropyl cellulose, sodium CMC, maltodextrins. 
Layering is classified into three categories: direct pelletizing, 
powder layering and solution or suspension layering [7, 8]. 
Materials suitable for use as starter cores in the production of coated 
pellets include sugar spheres consisting of saccharides and its 
derivatives like sugars, sucrose-starch mixtures, oligosaccharides 
and polysaccharides, microcrystalline cellulose spheres, pure drug 
crystals. Polymers which are plastic resins, inorganic substances like 
silica glass, hydroxyapatite and organic substances like activated 
carbon, acids like citric, fumaric, tartaric, ascorbic acids etc. can be 
employed [9]. 
Telmisartan was selected as a drug candidate for formulating drug 
coated pellets and solid dispersions for its improved dissolution 
characteristics. Telmisartan is an angiotensin II receptor blocker 
used for treatment of hypertension. This drug belongs to the BCS 
class II category and is highly insoluble in aqueous fluids. The 
absolute bioavailability of telmisartan is approximately 42-100%. 
After oral administration, the peak plasma concentration (Cmax) of 
telmisartan is reached after 1 to 2 h [10]. 
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The main aim of present investigation was to formulate telmisartan 
solid dispersions and fast dissolving pellets by using nonpareil sugar 
beads as inert core material with soluplus as binder and solubility 
enhancer, crospovidone as disintegrant and ethanol was used as 
solvent to prepare the coating suspension to coat on the sugar beads 
as a drug layer by pan coating technique. 
MATERIALS AND METHODS 
Materials 
Telmisartan was a gift sample from Pellets Pharma Ltd., Hyderabad. 
Soluplus, ethanol and HPMC E5 were procured from SD Fine Chem. 
Ltd., Mumbai. Crospovidone was a gift sample from M/S NATCO 
Pharma Ltd., Hyderabad. 
Estimation of telmisartan 
Validated UV Spectrophotometric method was used for the 
estimation of telmisartan. Telmisartan was estimated 
by measurement of absorbance at 296 nm in phosphate buffer of pH 
7.5. The method was validated for linearity, accuracy, precision and 
interference. The method obeyed Beer’s law in the range of 0–
10 µg/ml concentration. Relative error and coefficient of variance 
were determined based on the results from repeatedly 
assayed samples. Standard drug solution was repeatedly assayed for 
6 samples (n=6), and the relative error and coefficient of variance 
were found to be 0.72% and 1.5% respectively. There was 
no excipients interference observed [11, 12].  
Methods 
Preparation of solid dispersions by kneading method 
Solid dispersions of telmisartan in different concentrations of 
soluplus were prepared by kneading method. The required 
quantities of drug and soluplus were dissolved in the solvent ethanol 
to get a clear solution in a dry mortar. The mixture was kneaded for 
30 min by continuous trituration. Small volume of the solvent was 
added to maintain the mixture as thick slurry during kneading 
process. Trituration is continued until a dry mass was obtained. The 
mass obtained was further dried at 50 °C for 1 hour in a hot air oven. 
The dried product was powdered and passed through mesh no. 100 
in each case. Various solid dispersions and their drug to carrier 
ratios are indicated in table 1 [13-15]. 
 
Table 1: Composition of telmisartan solid dispersions prepared by kneading method using soluplus 
Formulation Composition Drug: Carrier ratio Telmisartan: Soluplus) 
TS1 Telmisartan: Soluplus 1:1 
TS 2 Telmisartan: Soluplus 1:2 
TS 3 Telmisartan: Soluplus 1:3 
TS 4 Telmisartan: Soluplus 1:4 
TS 5 Telmisartan: Soluplus 1:5 
 
Preparation of pellets by pan coating method 
A dispersion of crospovidone in purified water was prepared by 
using half of its quantity and it was initially applied on the sugar 
beads by using spray gun at a pan speed of 300 rpm while 
maintaining the temperature at 60 °C using IR lamp. The 
crospovidone coated beads were further dried at room 
temperature for 12 h. This coat acts as a base coat for applying the 
medicament on the beads. Coating solution was prepared by 
dissolving telmisartan, soluplus and remaining crospovidone in 
ethanol at different ratios. The crospovidone coated spheres then 
placed in a pan coater and coating solution was sprayed by using 
sprayer gun. Coating pan was operated at 300 rpm, while hot air is 
blown at 50 °C. Then these beads were further dried at room 
temperature for 12 h. The drug coated beads were finally coated 
with HPMC E5 dissolved in purified water by using spray gun at a 
pan speed of 300 rpm while maintaining the temperature at 50 °C 
using IR lamp. This coat acts as a protective layer and the finally 
coated beads were thoroughly dried in a tray drier at 60 °C for 1 
hour. Then these beads were stored in a desiccator for further use 
[16, 17]. Various pellet formulations and their drug to carrier 
ratios are indicated in table 2. 
 
Table 2: Composition of telmisartan pellet formulations prepared by pan coating method using soluplus 
Formulation Composition Drug: carrier ratio telmisartan: soluplus) 
TP1 Telmisartan: Soluplus 1:1 
TP2 Telmisartan: Soluplus 1:2 
TP3 Telmisartan: Soluplus 1:3 
TP4 Telmisartan: Soluplus 1:4 
TP5 Telmisartan: Soluplus 1:5 
 
Evaluation of physicochemical parameters on prepared granules 
The physical parameters such as particle size, friability, angle of 
repose and drug content were evaluated for prepared formulations. 
Particle size determination 
The average particle size of the prepared solid dispersions and pellet 
formulations was analyzed by sieve analysis method [18]. 
Friability test 
Roche friabilator was used to determine the friability. Pre-weighed 
pellets were placed in friabilator and rotated at a speed of 25 rpm 
for 4 min. The pellets were then re-weighed after removal of fine 
and the percentage of weight loss was calculated.  
Angle of repose determination 
Angle of repose was determined by passing the solid dispersions and 
pellet formulations through a funnel fixed to a burette stand at a 
particular height (4 cm). A graph paper was placed below the funnel 
on the table. The height and radius of pile were measured [19]. 
Angle of repose of the formulations was calculated using suitable 
formula. 
 
Where h is height and r is the radius of the pile. 
Drug content determination 
Different formulations of telmisartan equivalent to 20 mg was weighed 
and transferred into a 100 ml volumetric flask. To this, small quantity of 
methanol was added to dissolve. It was shaken occasionally for about 15 
min and the volume was made upto 100 ml by adding pH 7.5 phosphate 
buffer. The solution was filtered and the filtrate was subsequently 
diluted with pH 7.5 phosphate buffer and the absorbance was measured 
at 296 nm using pH 7.5 buffer as blank solution. 
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In vitro dissolution studies 
The dissolution test for prepared solid dispersions and pellets was 
carried out in USP Apparatus Type II (paddle) with 900 ml of pH 7.5 
phosphate buffer as dissolution medium. The temperature and 
rotations per minute (rpm) were maintained at 37±0.5 °C and 75, 
respectively. 5 ml samples were withdrawn at 5, 10, 15, 20, 30, 45 
and 60 min. A fresh volume of the medium was replaced with same 
volume to maintain the sink conditions and the constant volume 
throughout the experiment. The samples withdrawn were suitably 
diluted with same dissolution medium and the amount of drug 
dissolved was estimated by ultraviolet spectrophotometer (UV 
3000+) at 296 nm. The dissolution studies were carried out for 6 
times on all the formulations.  
Based on dissolution data, various dissolution parameters such as 
T50and DE30% first order constant and Hixon-Crowell constants were 
determined for various formulations. T50 is the time required for 
50% of the drug to dissolve in suitable dissolution medium. It can be 
measured by plotting a graph taking time in minutes on X-axis and 
cumulative percent drug dissolved on Y-axis. The dissolution 
efficiency can have a range of values depending on the time intervals 
chosen. In any case, constant time intervals should be chosen for 
comparison. The index DE30% would relate to the dissolution of drug 
from a particular formulation after 30 min and could only be 
compared with DE30% of other formulations. It was calculated using 
the dissolved percentage curves of the drug versus time. Here, the 
region between the area above the curve and the total area of the 
graph were used for calculation and expressed in percentage. 
Characterization of telmisartan formulations 
Based on the dissolution studies, the optimized formulations were 
selected and FTIR and DSC studies were performed to know the 
drug and polymer interactions. SEM analysis was performed for 
pellet formulation and its polymers to know the surface 
characteristics. 
Accelerated stability studies 
The optimized formulations (TS5 and TP3) were subjected to 
accelerated stability studies as per ICH guidelines. They were kept in 
separate petri dishes after preparation and stored in thermo stated 
oven at a temperature and relative humidity (RH) of 25±2 °C, 
60±5% RH for 6 mo and 40±2 °C, 75±5% RH for 3 mo. Then, they 
were evaluated for physical parameters, drug content and drug 
release studies. 
RESULTS AND DISCUSSION 
The compositions of various telmisartan formulations were given in 
table 3. 
 
Table 3: Composition of telmisartan solid dispersions and pellet formulations 
S. No. Ingredients (mg/10 doses) TS1 TS 2 TS 3 TS 4 TS 5 TP1 TP2 TP3 TP4 TP5 
1.  Telmisartan 200 200 200 200 200 200 200 200 200 200 
2.  Sugar Pellets --- --- --- --- --- 2000 2000 2000 2000 2000 
3.  Soluplus 200 400 600 800 1000 200 400 600 800 1000 
4.  Crospovidone --- --- --- --- --- 50 50 50 50 50 
5.  HPMC E5 --- --- --- --- --- 50 50 50 50 50 
6.  Ethanol q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. 
7.  Purified Water --- --- --- --- --- q. s. q. s. q. s. q. s. q. s. 
mg = milligram; q. s = quantity sufficient 
 
Evaluation of physicochemical parameters 
All the solid dispersions were having the particle size of 250–260 
µm, while the pellet formulations were found to have the particle 
size in the range of 840–845 µm. Friability loss for all pellet 
formulations were within the limits i.e.<0.8%. Angle of repose values 
indicated that all solid dispersion formulations were having good 
flow characteristics with angle of repose value ranging from 22–24 °, 
whereas pellet formulations were having excellent flow properties 
with angle of repose 16–18 °. Drug content was estimated for all 
formulations and found to be highly uniform in range of 18.20–19.78 
mg/dose. Physicochemical parameters evaluated for telmisartan 
formulations indicated that all formulations were stable and 
possessing required limits as per literature. The values of 
physicochemical parameters of telmisartan formulations were given 
in table 4. 
  
Table 4: Evaluation of physicochemical parameters of telmisartan formulations 




Angle of repose ( °) Drug content (mg/dose) 
mean±SD 
1.  TS1 250±0.12 ---- 24 18.20±0.36 
2.  TS2 255±0.39 ---- 22 19.08±0.19 
3.  TS3 255±0.46 ---- 23 19.20±0.26 
4.  TS4 260±0.36 ---- 22 19.17±0.43 
5.  TS5 250±0.39 ---- 22 19.34±0.42 
6.  TP1 840±0.27 0.2 18 19.38±0.12 
7.  TP2 845±0.38 0.2 18 19.76±0.32 
8.  TP3 840±0.29 0.1 16 19.78±0.22 
9.  TP4 840±0.52 0.13 17 19.65±0.46 
10.  TP5 845±0.46 0.12 17 19.64±0.12 
 n=3; µm=micrometer; %w/w= percentage weight by weight; SD= Standard deviation 
 
In vitro dissolution studies 
Dissolution profiles indicated that telmisartan pure drug released to 
the extent of 45.77% whereas the marketed formulation (TAZLOC-20) 
was released to the extent of 81.35% at one hour. Solid dispersions 
TS1–TS5 found to release the drug from 79.64 to 93.06% respectively. 
The prepared fast dissolving solid dispersions tend to increase drug 
release from 1.740 to 2.033 folds when compared to pure drug. Pellet 
formulationsTP1-TP5 was found to release the drug from 89.25–
99.34%. These fast dissolving pellet formulations tend to increase the 
drug release from 1.949–2.170 folds when compared to pure drug and 
1.097–1.221 folds when compared to the marketed formulation. It was 
observed that the dissolution rate of the solid dispersion formulation 
TS5 showed better dissolution rate to the extent of 1.143 folds and 
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2.033 folds when compared to the marketed formulation and pure 
drug respectively. Similarly, formulation TP3containing 1:3 ratio of 
telmisartan to soluplus the dissolution rate is increased to the extent 
of 1.221 folds when compared to marketed formulation and 2.170 
when compared to pure drug. It was observed that the rate of 
dissolution is greatly increased with pellet formulations than 
compared to solid dispersions prepared. Formulation TP3 pellets 
containing1:3 drug to polymer ratio exhibited better release 
characteristics when compared to formulation TS5 containing 1:5 ratio 
of drug and polymer. This was due to increased surface area of the 
pellet formulations. Dissolution profiles were given in fig. 1 and 2. Past 
studies performed by several others also revealed that other than 
soluplus, polymers like PEG 6000, PVP K30, Eudragit L 100 can also be 
used to enhance the solubility of telmisartan [20, 21]. Other agents like 
Poloxamer 188, PVP K25 and sodium starch glycolate can also 
increase the dissolution rates of telmisartan [22, 23]. All these carriers 
enhance dissolution of poorly water soluble drugs depending upon the 
drug to carrier ratio. 
 
 
Fig. 1: Dissolution profiles of telmisartan fast dissolving solid dispersions (Results are expressed as mean±SD, n=3) 
 
 
Fig. 2: Dissolution profiles of telmisartan fast dissolving pellets (Results are expressed as mean±SD, n=3) 
 
Dissolution parameters such as T50 and DE30% values were 
calculated for all the formulations. T50 for solid dispersions range 
from 9.75 to 19 min. Similarly, T50 for pellet formulation ranges from 
9 to 17 min. DE30% values for solid dispersions ranges from 38.3 to 
60%. DE30% values for pellet formulations ranges from 43.3 to 
59.1%. Majority of the formulations displayed first order release 
kinetics and were found to be linear with R2 values in the range of 
0.926 to 0.994. The Hixon crowell constants for all the formulations 
were found to be linear with R2 values ranging from 0.880 to 0.997 
indicating that the drug release is by continuous depletion of the 
drug from the film formed across the spherical bead per unit weight. 
The results were indicated in table 5. 
 
Table 5: In vitro dissolution kinetics of telmisartan formulations 
S. No. Formulations T50 (min) DE30 
(%) 
First order Hixon crowell 
R2 K1 (min-1) R2 KHC  (mg1/3) 
1 Pure drug -- 12 0.994 0.010 0.995 0.008 
2 Marketed formulation (TAZLOC-20) 17.5 40 0.926 0.029 0.880 0.018 
3 TS1 19 38.3 0.972 0.025 0.968 0.015 
4 TS 2 18 43.3 0.951 0.027 0.972 0.014 
5 TS 3 14 46.6 0.965 0.029 0.971 0.016 
6 TS 4 9.75 55.8 0.931 0.037 0.905 0.018 
7 TS 5 9.75 60 0.940 0.043 0.903 0.021 
8 TP1 17 43.3 0.986 0.034 0.997 0.019 
9 TP2 9.5 53.3 0.985 0.045 0.971 0.022 
10 TP3 9 59.1 0.958 0.076 0.989 0.032 
11 TP4 10 56.6 0.981 0.064 0.991 0.029 
12 TP5 10 55.8 0.991 0.055 0.976 0.026 
 T50= Time required for 50% of drug release; DE30=Dissolution efficiency within 30 min; R2= Regression coefficient; K1= First order rate constant; 
KHC= Hixon crowell rate constant 
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The drug and excipient interactions were further characterized by IR 
Spectral analysis. FTIR Spectra of telmisartan pure drug, soluplus, 
optimised telmisartan solid dispersion and optimized telmisartan 
pellet formulation were obtained by KBr pelletization process. 
Spectra exhibited peaks, indicating the presence of-C-H Stretching 
and bending,-C=O Stretching, aromatic Para Substitution and–NH 
Wagging. Thus the FTIR Spectral analysis indicated that there were 
no drug interactions. The detailed spectra elucidations were shown 
in fig. 3, 4, 5 and 6 and indicated in table 6. 
 
 
Fig. 3: FTIR interpretation of telmisartan 
 
 
Fig. 4: FTIR interpretation of soluplus 
 
 
Fig. 5: FTIR spectra of optimized solid dispersion (TS5) 
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Fig. 6: FTIR spectra of optimized pellet formulation (TP3) 
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Fig. 7: DSC Images of (a) Telmisartan (b) Soluplus (c) Optimized Solid Dispersion (TS5) (d) Pellets (e) Optimized Pellet Formulation (TP3) 
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Table 6: FTIR spectrum interpretation for telmisartan formulations 
Functional group Wave number (cm-1) 
Pure drug Soluplus TS5 TP3 
C-H Stretching 3134.19 3197.51 3170.95 3397.06 
C=O Stretching 1695.79 1617.59 1616.73 1633.72 
C-H Bending 1402.49 1398.97 1401.25 1401.41 
Para Substitution, aromatic 863.06 --- 863.06 866.00 
NH-Wagging 741.28 --- 741.40 683.93 
 
DSC thermograms 
DSC thermograms indicated that the broad endothermic peak for 
telmisartan was observed at 278.96 °C, for soluplus, a narrow 
endothermic peak was observed at 177.46 °C, a broad endothermic 
peak at 341.79 °C and a sharp exothermic peak at 363.73 °C. The 
solid dispersions prepared by soluplus exhibited broad endothermic 
peaks at 318.26 °C and 380.12 °C. This indicated that the solid 
dispersions prepared were highly stable with molecular entrapment 
of telmisartan in soluplus. The sharp endothermic peak was 
observed at 189.10 °C and a broad peak at 237.15 °C for pellets. 
Similarly, a sharp endothermic peak at 193.17 °C, a broad 
endothermic peak at 221.20 °C and a small exothermic peak at 
320.60 °C for soluplus was observed in the coated pellets indicated 
that the drug is molecularly entrapped in soluplus on the coated 
surface of sugar pellets. These studies indicated that there were no 
chemical interactions or decomposition between drug and polymers 
used in the formulations with the absence of additional peaks. The 
values were indicated in fig. 7. 
Scanning electron microscopy (SEM) 
The SEM analysis revealed the structure of telmisartan as 
crystalline and soluplus as spherical which were indicated in fig. 8. 
Solid dispersions prepared by kneading technique were found to 
be in fine amorphous form of dispersion where drug is totally 
entrapped into soluplus. The uncoated and coated sugar beads 
exhibited smooth surface with a uniform coating upon the coated 








(d)       (e) 
Fig. 8: Scanning electron microscopic images of (a) Telmisartan (b) Soluplus (c) Optimized Solid Dispersion (TS5) (d) Pellets (e) Optimized 
Pellet Formulation (TP3) 
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Accelerated stability studies 
The optimized formulations TS5 and TP3 were subjected to 
accelerated stability studies as per ICH guidelines after storage at 
different conditions. Physical parameters and drug release studies 
were carried out on these formulations and the results were 
indicated in table 7 and fig. 9, 10 respectively. 
 
Table 7: Parameters of formulations TS5 and TP3 under accelerated stability conditions 




Angle of repose ( °) Drug content (mg/dose) 
mean±SD 
TS5 Before Storage 250±0.39 ---- 22 19.34±0.42 
25±2 °C, 60±5% RH 250±0.31 ---- 22 19.29±0.22 
40±2 °C, 75±5% RH 250±0.29 ---- 23 19.27±0.39 
TP3 Before Storage 840±0.29 0.1 16 19.78±0.22 
25±2 °C, 60±5% RH 840±0.26 0.11 16 19.76±0.21 
40±2 °C, 75±5% RH 840±0.21 0.12 17 19.74±0.26 
n=3; RH = Relative humidity; SD= Standard deviation 
 
 
Fig. 9: Drug release studies of TS5 before and after storage at different conditions (Results are expressed as mean±SD, n=3) 
 
 
Fig. 10: Drug release studies of TP3 before and after storage at different conditions (Results are expressed as mean±SD, n=3) 
 
There was no significant change observed in physical parameters 
and drug release even stability studies at various storage conditions 
and indicated that these formulations were found to be stable. 
CONCLUSION 
Telmisartan solid dispersions and fast dissolving pellet formulations 
were prepared by using soluplus as a fast dissolving carrier. Among 
the various formulations prepared formulation TS5and TP3 prepared 
by solid dispersion technique and pelletization technique exhibited 
faster dissolution than compared to the marketed formulation and 
hence they are considered as optimized formulations. Hence it is 
concluded that pellet coating technique is found to be simple and 
stable when compared to other conventional solid dispersion 
techniques. 
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